Targeting the Hedgehog pathway in cancer: can the spines be smoothened?
- PMID: 21367749
- DOI: 10.1158/1078-0432.CCR-11-0211
Targeting the Hedgehog pathway in cancer: can the spines be smoothened?
Abstract
Aberrant Hedgehog (Hh) pathway signaling has been suggested to play a role in the development of multiple solid tumors and hematologic malignancies. GDC-0449 is a novel first-in-human, first-in-class smoothened (SMO) inhibitor, which has completed its phase I evaluation and achieved proof of concept in tumors with Hh pathway mutations.
©2011 AACR.
Comment on
-
Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding.Clin Cancer Res. 2011 Apr 15;17(8):2512-20. doi: 10.1158/1078-0432.CCR-10-2736. Epub 2011 Feb 7. Clin Cancer Res. 2011. PMID: 21300760 Free PMC article. Clinical Trial.
-
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.Clin Cancer Res. 2011 Apr 15;17(8):2502-11. doi: 10.1158/1078-0432.CCR-10-2745. Epub 2011 Feb 7. Clin Cancer Res. 2011. PMID: 21300762 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous